Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Ferguson

Nurse Practitioner, Family Lawrence, KS Nurse Practitioner

NPI 1376895318 CMS profile 10601400

3211 S Iowa St Ste 100, Lawrence, KS 66046

Open in the dashboard

General payments

$6,512

398 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Ferguson of Lawrence, KS is reported in the CMS Open Payments database as having received $6,512 across 398 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,166 64
2024 General $1,541 88
2023 General $1,057 65
2022 General $1,434 99
2021 General $1,314 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Ferguson
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Melissa Ferguson were reported at $1,166. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Melissa Ferguson Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,314 $124 $35–$379 $132
2022 $1,434 $141 $44–$430 $149
2023 $1,057 $154 $49–$476 $160
2024 $1,541 $165 $51–$504 $164
2025 $1,166 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,586 89 payments
  2. Novo Nordisk Inc $944 64 payments
  3. Lilly USA, LLC $552 38 payments
  4. AstraZeneca Pharmaceuticals LP $475 27 payments
  5. Teva Pharmaceuticals USA, Inc. $437 21 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $372 23 payments
  7. Pfizer Inc. $231 18 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $219 13 payments
  9. Amgen Inc. $215 16 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $205 18 payments
  11. Other $1,277 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,512 398 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,135 61 payments
  2. Ozempic $530 33 payments
  3. RYBELSUS $442 28 payments
  4. XIFAXAN $372 23 payments
  5. MOUNJARO $355 23 payments
  6. UBRELVY $295 20 payments
  7. AIRSUPRA $284 14 payments
  8. FARXIGA $265 13 payments
  9. AJOVY $259 13 payments
  10. NURTEC ODT $256 21 payments
  11. Other $3,482 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

2,157

Median for Nurse Practitioner: 389

Drug cost

$180,490

Median for Nurse Practitioner: $21,885

Branded share of claims

25.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 50 $66,284
Eliquis Apixaban Brand 41 $38,022
Farxiga Dapagliflozin Propanediol Brand 22 $18,902
Jardiance Empagliflozin Brand 18 $15,561
Breo Ellipta Fluticasone/Vilanterol Brand 19 $7,758
Fetzima Levomilnacipran Hcl Brand 12 $5,785
Incruse Ellipta Umeclidinium Bromide Brand 11 $4,139
Advair Hfa Fluticasone Propion/Salmeterol Brand 11 $3,365
Albuterol Sulfate Hfa Albuterol Sulfate Brand 71 $1,227
Synthroid Levothyroxine Sodium Brand 13 $1,049

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$39,148

Of which drugs: $6,670

Medicare patients

205

Average age 71

Services billed

989

133 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 38%
Depression 20%
Diabetes 18%
Ischemic heart disease 18%
Osteoporosis 15%
Cancer 11%
Atrial fibrillation 9%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 12 12 $1,712
Vaccine for influenza for injection into muscle 90662 Office 12 12 $900

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $170
$170 — —
MOUNJARO
  • Lilly USA, LLC $143
$143 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $134
$134 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $105
$105 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

398 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record